Literature DB >> 8892022

A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency.

P Vreken1, A B Van Kuilenburg, R Meinsma, G P Smit, H D Bakker, R A De Abreu, A H van Gennip.   

Abstract

Dihydropyrimidine dehydrogenase (DPD) deficiency is an autosomal recessive disease characterized by thymine-uraciluria and associated with a variable clinical phenotype. In order to identify the molecular defect underlying complete DPD deficiency in a Dutch patient previously shown to have a 165 base pair deletion in the mature DPD mRNA, we cloned the genomic region encompassing the skipped exon and its flanking intron sequences. Sequence analysis revealed that the patient was homozygous for a single G-->A point mutation in the invariant GT dinucleotide splice donor site downstream of the skipped exon. The same mutation was identified in another, unrelated, Dutch patient. Because this mutation destroys a unique MaeII restriction site, rapid screening using restriction enzyme cleavage of the amplified genomic region encompassing this mutation is possible. Analysis of 50 controls revealed no individuals heterozygous for this mutation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8892022     DOI: 10.1007/bf01799841

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  29 in total

1.  Identification of RNA splicing errors resulting in human ornithine transcarbamylase deficiency.

Authors:  R P Carstens; W A Fenton; L R Rosenberg
Journal:  Am J Hum Genet       Date:  1991-06       Impact factor: 11.025

2.  Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome.

Authors:  B E Harris; J T Carpenter; R B Diasio
Journal:  Cancer       Date:  1991-08-01       Impact factor: 6.860

3.  Exon definition may facilitate splice site selection in RNAs with multiple exons.

Authors:  B L Robberson; G J Cote; S M Berget
Journal:  Mol Cell Biol       Date:  1990-01       Impact factor: 4.272

4.  Splice junctions, branch point sites, and exons: sequence statistics, identification, and applications to genome project.

Authors:  P Senapathy; M B Shapiro; N L Harris
Journal:  Methods Enzymol       Date:  1990       Impact factor: 1.600

5.  An improved PCR method for walking in uncloned genomic DNA.

Authors:  P D Siebert; A Chenchik; D E Kellogg; K A Lukyanov; S A Lukyanov
Journal:  Nucleic Acids Res       Date:  1995-03-25       Impact factor: 16.971

6.  Dihydropyrimidine dehydrogenase deficiency presenting with psychomotor retardation and ocular abnormalities.

Authors:  H D Bakker; M E Rubio Gozalbo; A H van Gennip
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

7.  Molecular diagnosis.

Authors:  D I Hoar
Journal:  Can Fam Physician       Date:  1987-02       Impact factor: 3.275

8.  Identification of two new aberrant splicings in the ornithine carbamoyltransferase (OCT) gene in two patients with early and late onset OCT deficiency.

Authors:  T Matsuura; R Hoshide; S Komaki; K Kiwaki; F Endo; S Nakamura; T Jitosho; I Matsuda
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

9.  GT to AT transition at a splice donor site causes skipping of the preceding exon in phenylketonuria.

Authors:  J Marvit; A G DiLella; K Brayton; F D Ledley; K J Robson; S L Woo
Journal:  Nucleic Acids Res       Date:  1987-07-24       Impact factor: 16.971

10.  Dihydropyrimidine dehydrogenase activity in human blood mononuclear cells.

Authors:  M Tuchman; R V Roemeling; W A Hrushesky; R B Sothern; R F O'Dea
Journal:  Enzyme       Date:  1989
View more
  24 in total

Review 1.  Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-05-31

2.  Dihydropyrimidine dehydrogenase deficiency: a novel mutation and expression of missense mutations in E. coli.

Authors:  P Vreken; A B van Kuilenburg; R Meinsma; F A Beemer; M Duran; A H van Gennip
Journal:  J Inherit Metab Dis       Date:  1998-06       Impact factor: 4.982

3.  Severe 5-fluorouracil toxicity caused by reduced dihydropyrimidine dehydrogenase activity due to heterozygosity for a G-->A point mutation.

Authors:  A B van Kuilenburg; P Vreken; L V Beex; R A De Abreu; A H van Gennip
Journal:  J Inherit Metab Dis       Date:  1998-06       Impact factor: 4.982

4.  Clinical variability in three Danish patients with dihydropyrimidine dehydrogenase deficiency all homozygous for the same mutation.

Authors:  E Christensen; I Cezanne; S Kjaergaard; H Hørlyk; V Faurholt Pedersen; P Vreken; A B van Kuilenburg; A H Van Gennip
Journal:  J Inherit Metab Dis       Date:  1998-06       Impact factor: 4.982

5.  Identification of novel point mutations in the dihydropyrimidine dehydrogenase gene.

Authors:  P Vreken; A B Van Kuilenburg; R Meinsma; A H van Gennip
Journal:  J Inherit Metab Dis       Date:  1997-07       Impact factor: 4.982

Review 6.  Pharmacogenetics: a tool for individualizing antineoplastic therapy.

Authors:  F Innocenti; L Iyer; M J Ratain
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

Review 7.  Inborn errors of pyrimidine degradation: clinical, biochemical and molecular aspects.

Authors:  A H van Gennip; N G Abeling; P Vreken; A B van Kuilenburg
Journal:  J Inherit Metab Dis       Date:  1997-06       Impact factor: 4.982

8.  Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects.

Authors:  S A Ridge; J Sludden; O Brown; L Robertson; X Wei; A Sapone; P M Fernandez-Salguero; F J Gonzalez; P Vreken; A B van Kuilenburg; A H van Gennip; H L McLeod
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

9.  Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule.

Authors:  Elena Magnani; Enrico Farnetti; Davide Nicoli; Bruno Casali; Luisa Savoldi; Chiara Focaccetti; Corrado Boni; Adriana Albini; Maria Banzi
Journal:  Intern Emerg Med       Date:  2013-04-13       Impact factor: 3.397

10.  Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity.

Authors:  André B P van Kuilenburg; Judith Meijer; Adri N P M Mul; Rutger Meinsma; Veronika Schmid; Doreen Dobritzsch; Raoul C M Hennekam; Marcel M A M Mannens; Marion Kiechle; Marie-Christine Etienne-Grimaldi; Heinz-Josef Klümpen; Jan Gerard Maring; Veerle A Derleyn; Ed Maartense; Gérard Milano; Raymon Vijzelaar; Eva Gross
Journal:  Hum Genet       Date:  2010-08-29       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.